Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of
diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study

Asmaa Mohamed; Mariem Elfeky; Shereen Elshorbagy; Nabila Hefzi; Tamer Oraby; Waleed Abdelhady; Mahmoud Eldein; Ahmed Embaby; Ehab Oraby

doi:10.5114/wo.2022.115675

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2022
vol. 26

Send email

Copy url:

abstract:

Original paper

Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study

Asmaa Hussein Mohamed

¹

,

Mariem A. Elfeky

¹

,

Shereen Elshorbagy

²

,

Nabila Hefzi

³

,

Tamer Oraby

⁴

,

Waleed A. Abdelhady

⁵

,

Mahmoud Sharaf Eldein

⁶

,

Ahmed Embaby

⁶

,

Ehab M. Oraby

⁷

Department of Pathology, Zagazig University Faculty of Medicine, Zagazig, Egypt

Department of Medical Oncology, Faculty of Medicine, Zagazig University Zagazig, Egypt

Department of Clinical Oncology Oncology, Faculty of Medicine, Zagazig University Zagazig, Egypt

Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Zagazig, Egypt

Department of General Surgery, Faculty of Medicine, Zagazig, Egypt

Department of Internal Medicine, Faculty of Medicine, Zagazig, Egypt

Department of General Surgery, Faculty of Medicine, Benha, Egypt

Contemp Oncol (Pozn) 2022; 26 (1): 49–58

DOI: https://doi.org/10.5114/wo.2022.115675

Online publish date: 2022/03/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Mohamed AH, Elfeky MA, Elshorbagy S, et al. Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of
diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study. Contemporary Oncology/Współczesna Onkologia. 2022;26(1):49-58. doi:10.5114/wo.2022.115675.

APA

Mohamed, A. H., Elfeky, M. A., Elshorbagy, S., Hefzi, N., Oraby, T.,  & Abdelhady, W. A. et al. (2022). Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of
diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study. Contemporary Oncology/Współczesna Onkologia, 26(1), 49-58. https://doi.org/10.5114/wo.2022.115675

Chicago

Mohamed, Asmaa H, Mariem A Elfeky, Shereen Elshorbagy, Nabila Hefzi, Tamer Oraby, Waleed A Abdelhady,  and Mahmoud S Eldein et al. 2022. "Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of
diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study". Contemporary Oncology/Współczesna Onkologia 26 (1): 49-58. doi:10.5114/wo.2022.115675.

Harvard

Mohamed, A., Elfeky, M., Elshorbagy, S., Hefzi, N., Oraby, T., Abdelhady, W., Eldein, M., Embaby, A.,  and Oraby, E. (2022). Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of
diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study. Contemporary Oncology/Współczesna Onkologia, 26(1), pp.49-58. https://doi.org/10.5114/wo.2022.115675

MLA

Mohamed, Asmaa et al. "Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of
diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study." Contemporary Oncology/Współczesna Onkologia, vol. 26, no. 1, 2022, pp. 49-58. doi:10.5114/wo.2022.115675.

Vancouver

Mohamed A, Elfeky M, Elshorbagy S, Hefzi N, Oraby T, Abdelhady W et al. Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of
diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study. Contemporary Oncology/Współczesna Onkologia. 2022;26(1):49-58. doi:10.5114/wo.2022.115675.

PlumX metrics:

Introduction
Diffuse large B-cell non- Hodgkin lymphoma (DLBCL) is the largest common category of adult lymphoma. Recurrence and treatment resistance occurs in one-third of cases, triggering them to the progressive stage of DLBCL after treatment. Detection of novel predictive and prognostic biomarkers leads to improvement of its treatment and prognosis.

Aim of the study
To assess the prognostic roles of protein expression of myeloid differentiation factor 88 (MYD88) and transducin ()-like receptor 1 (TBLR1) in tissues of DLBCL patients.

Material and methods
In the current study we included tissues from 100 cases of DLBCL. For immunohistochemistry, tissues were stained with MYD88 and TBLR1. We followed patients for about 3 years, and then we correlated their expression with clinicopathological and prognostic parameters.

Results
Higher MYD88 and TBLR1 expressions were associated with presence of B symptoms, fever, night sweat, advanced stage, bone marrow involvement and bulky nodal size, presence of extra-nodal extension, unfavourable relapse-free survival, and unfavourable overall survival rates (p < 0.001).

Conclusions
overexpression of MYD88 and TBLR1 expression was present in DLBCL patients and was associated with unfavourable clinicopathological and prognostic parameters.

keywords:

Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study

Asmaa Hussein Mohamed 1 , Mariem A. Elfeky 1 , Shereen Elshorbagy 2 , Nabila Hefzi 3 , Tamer Oraby 4 , Waleed A. Abdelhady 5 , Mahmoud Sharaf Eldein 6 , Ahmed Embaby 6 , Ehab M. Oraby 7

MYD88, TBLR1, immunohistochemistry, diffuse large B-cell lymphoma, prognosis

Asmaa Hussein Mohamed

¹

,

Mariem A. Elfeky

¹

,

Shereen Elshorbagy

²

,

Nabila Hefzi

³

,

Tamer Oraby

⁴

,

Waleed A. Abdelhady

⁵

,

Mahmoud Sharaf Eldein

⁶

,

Ahmed Embaby

⁶

,

Ehab M. Oraby

⁷